STAA at a glance
STAAR SURGICAL CO (STAA, SEC CIK 718937) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as August 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended January 2, 2026 (FY2025), STAAR SURGICAL CO (STAA) reported revenue of $239.4 million (down 23.7% from FY2024) and a net loss of $80.4 million. Diluted EPS was -$1.62.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding STAAR SURGICAL CO (STAA) shares worth $537.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $239.4M
- −23.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $537.3M · +1 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 7.01 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jan 2, 2026
Business Overview
- Core business: development and sales of Implantable Collamer Lenses (ICLs) for treatment of myopia and refractive errors
- New product emphasis: full launch of EVO+ premium larger optic lens in China and planned introduction of additional lens sizes for surgical flexibility
- Strategic shift: heightened focus on growth, investment, and innovation amid market headwinds, including leadership realignment and cost reductions in 2025
- Quantitative metric: net sales decline 23.7% in 2025 to $239.4M driven by 32% drop in APAC region, especially China; R&D spend $40.1M (16.7% of sales)
- Noteworthy fact: terminated proposed merger with Alcon in early 2026 after incurring $17.1M merger-related costs in 2025
Risk Factors
- Termination of Alcon Merger Agreement January 2026; $17.1 million Merger transaction costs in fiscal 2025
- China macroeconomic downturn causing net sales drop from $313.9M in 2024 to $239.4M in 2025, with China distributor sales down from $162.3M to $77.8M
- Dual manufacturing sites in U.S. and Switzerland increasing costs, pressuring gross margins due to lower site utilization
- Elevated China distributor inventory post-2024 led to reduced 2025 purchases, creating channel inventory risk and sales volatility
- Key-person and governance risks from Cooperation Agreement with largest stockholder Broadwood involving leadership changes and $7.0 million reimbursement
Management Discussion & Analysis
- No revenue, profitability, segment, cash flow, or forward-looking data disclosed in the MD&A section provided
AI summary of the STAA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 3, 2026
Risk Factors
- No risk factors provided; excerpt contains only Other Information, Exhibits, and Signatures
- CEO transition risk indicated by Warren Foust’s offer letter, effective August 4, 2026
- Leadership incentive risk indicated by performance stock option grants to Warren Foust and Deborah Andrews
AI summary of the STAA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Bailey appointed Chief Commercial Officer, adding dedicated leadership for commercial strategy
- Executive change may influence sales execution, market expansion, and revenue growth priorities
Item 5.02: Departure/Appointment of Directors or Principal Officers
- David Bailey appointed Chief Commercial Officer effective September 8, 2026, returning with prior CEO and international operations experience
- CHF 462,825 annual base salary, approximately $575,000, prorated for 2026
Item EX-99.1: Item EX-99.1
- Former CEO David Bailey appointed Chief Commercial Officer, rejoining executive committee and reporting to CEO Warren Foust
- Mandate centered on accelerating revenue growth and expanding EVO ICL adoption as laser refractive volumes decline globally
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended July 3, 2026
- Press release furnished as Exhibit 99.1 contains the reported financial figures and operating details
Item EX-99.1: Item EX-99.1
- Q2 net sales $93.5M, up 111% YoY, driven by China sales of $52.3M and EVO+ adoption
- China represented over 50% of revenue, with market-share gains but heightened geographic concentration risk
Item 7.01: Regulation FD Disclosure
- Management conference call scheduled August 12, 2026 at 5:30 p.m. Eastern
- Discussion covers quarterly results for the quarter ended August 12, 2026
AI summaries of STAA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STAA
Don't miss the next STAA filing
- Alerts as it files. A push when STAA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STAA, by share count.
- Ask anything. An AI agent that reads every STAA filing and answers with sources.
STAA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| ANDREWS DEBORAH J | M | Aug 14, 2026 | 5,233 | - |
| Foust Warren | M | Aug 14, 2026 | 3,666 | - |
| ANDREWS DEBORAH J | A | Aug 14, 2026 | 4,975 | - |
| ANDREWS DEBORAH J | A | Aug 14, 2026 | 29,159 | - |
| Foust Warren | M | Aug 14, 2026 | 7,331 | - |
| Foust Warren | F | Aug 14, 2026 | 3,730 | $26.18 |
| ANDREWS DEBORAH J | M | Aug 14, 2026 | 5,233 | - |
| ANDREWS DEBORAH J | F | Aug 14, 2026 | 2,662 | $26.18 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $313.9M | $239.4M |
| Gross Profit | - | $239.6M | $182.4M |
| Operating Income | - | -$12.6M | -$91.7M |
| Net Income | - | -$20.2M | -$80.4M |
| Gross Margin | - | 76.3% | 76.2% |
| Op. Margin | - | -4.0% | -38.3% |
| Net Margin | - | -6.4% | -33.6% |
| Balance Sheet | |||
| Total Assets | $488.7M | $509.5M | $451.7M |
| Equity | $386.0M | $397.3M | $344.2M |
| ROE | - | -5.1% | -23.4% |
| Per Share | |||
| EPS | - | $-0.41 | $-1.62 |
| Cash Flow | |||
| Operating CF | - | $15.7M | -$34.2M |
| CapEx | - | $23.4M | $5.8M |
Source: XBRL data in STAAR SURGICAL CO (STAA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate STAA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $537.3M |
| Q1 2026 | 28 | $356.2M |
| Q4 2025 | 28 | $452.2M |
| Q3 2025 | 27 | $478.4M |
| Q2 2025 | 28 | $342.1M |
| Q1 2025 | 25 | $230.8M |
| Q4 2024 | 21 | $289.3M |
| Q3 2024 | 19 | $254.5M |
- Goldman Sachs Group+1.08M (+101%)
- Renaissance Technologies LLC+205.2K (+152%)
- Bank of America Corp+119.0K (+184%)
- JPMorgan Chase & Co+75.0K (+201%)
- BlackRock+65.0K (+1%)
- Citadel Advisors LLC−826.0K (-78%)
- Two Sigma Investments−449.3K (-80%)
- Morgan Stanley−183.2K (-12%)
- Vanguard Portfolio Management LLC−144.0K (-7%)
- Vanguard Capital Management LLC−137.9K (-8%)
- AQR Capital Management+13.0K
- Raymond James Financial+12.0K
- Millennium Management−165.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STAA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 12, 2026 | Jul 3, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 10-Q | May 13, 2026 | Apr 3, 2026 | Analysis | |
| 8-K | May 13, 2026 | - | Analysis |
Related Health Care companies
- BLCO · Bausch & Lomb CorpOphthalmic Goods
- COO · Cooper Companies (The)Ophthalmic Goods
- EYE · National Vision Holdings, Inc.Ophthalmic Goods
- RXST · RxSight, Inc.Ophthalmic Goods
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
STAA SEC filings: frequently asked questions
Which institutions hold STAA stock?
As of June 30, 2026, the largest STAAR SURGICAL CO (STAA) holders among the 13F filers tracked by SignalX were BlackRock ($193.1 million), Goldman Sachs Group ($61.7 million), Vanguard Portfolio Management LLC ($56.8 million), State Street Corp ($50.8 million), Vanguard Capital Management LLC ($44.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STAA's revenue in fiscal year 2025?
For the fiscal year ended January 2, 2026 (FY2025), STAAR SURGICAL CO (STAA) reported revenue of $239.4 million (down 23.7% from FY2024) and a net loss of $80.4 million. Diluted EPS was -$1.62. The figures come from the XBRL data in the 10-K.
What are the main risks in STAA's latest 10-K?
In the 10-K filed March 3, 2026, STAAR SURGICAL CO (STAA) flagged: Termination of Alcon Merger Agreement January 2026; $17.1 million Merger transaction costs in fiscal 2025. China macroeconomic downturn causing net sales drop from $313.9M in 2024 to $239.4M in 2025, with China distributor sales down from $162.3M to $77.8M. (AI summary of the Risk Factors section.)
What did STAA report in its latest 8-K?
STAAR SURGICAL CO (STAA) filed an 8-K on September 10, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Bailey appointed Chief Commercial Officer, adding dedicated leadership for commercial strategy.
What are the latest STAA SEC filings?
STAAR SURGICAL CO (STAA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on August 18, 2026.
What is STAA's SEC CIK number?
STAAR SURGICAL CO (STAA)'s SEC Central Index Key (CIK) is 718937. EDGAR lists every STAA filing under that number.
Ask anything about STAA
The research agent reads STAA's filings, financials, insider trades and 13F holders, then answers with sources.